Cost Effectiveness of Health

Improving diversity in clinical drug trials

Erika Grotto
September 10, 2024 10:05 am

Erika is joined by Quintin Maidment, a vice president at CTRx Pathways, to discuss why diversity is critical in clinical drug trials and what barriers stand in the way. In the Beyond the News segment, Nick and Shawn discuss the controversy around efforts by Johnson & Johnson to create a rebate program around 340B drug pricing.

About the Author

Erika Grotto

is a senior editor at HFMA and is based in Downers Grove, Ill.
See All Articles

Related Tags

Advertisements

googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text1' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text2' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text3' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text4' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text5' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text6' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-text7' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-leaderboard' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-cube1' ); } );
googletag.cmd.push( function () { googletag.display( 'hfma-gpt-cube2' ); } );

Recent Cost Effectiveness of Health

FTC takes legal action against pharmacy benefit managers, citing a distorted drug-pricing structure

David Johnson: 10 forces are combining to disrupt healthcare’s status quo

ONC issues proposed technical standards to improve health information sharing

googletag.cmd.push( function () { googletag.display( 'hfma-gpt-cube3' ); } );
Recommended Articles